Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Becton Dickinson to buy CareFusion for $12 bln in cash, stock

Sun, 05th Oct 2014 21:50

(Adds background, CEO comments)

By Deena Beasley

Oct 5 (Reuters) - Medical equipment supplier BectonDickinson & Co has agreed to buy CareFusion Corp, a maker of infusion pumps and other medical devices,for $12.2 billion in cash and stock, marking the latestmultibillion-dollar healthcare sector deal.

Becton said on Sunday it would pay a total of $58.00 a share- $49.00 in cash and 0.0777 of a share of Becton Dickinson - foreach share of CareFusion, representing a premium of 26 percentto the closing price on Oct. 3.

The acquisition, recommended by the boards of bothcompanies, is aimed at combining the two U.S.-based companies'complementary products for preparing, administering andmonitoring patient medications while also extending theirgeographical reach.

BD makes products to deliver and administer drugs, likedisposable needles, syringes and IV (intravenous) catheters,while CareFusion makes products to store the drugs and todeliver them, such as infusion pumps.

A combined company "could improve patient safety plus reducecosts at the same time," said Vincent Forlenza, BectonDickinson's chairman, chief executive officer and president in atelephone interview.

Cost-related healthcare reforms, including those mandatedunder President Barack Obama's Affordable Care Act, have spurredconsolidation for U.S. health systems and hospitals, the maincustomer for both Becton Dickinson and CareFusion.

"This is an industry that from a customer perspective isconsolidating," said Kieran Gallahue, CareFusion's chairman andCEO. "Healthcare systems around the globe are looking forcompanies that can bring greater scale to them - it is a way todrive down costs while improving safety at the same time."

Forlenza said Becton's geographic reach - around 60 percentof its sales are outside of the United States and 25 percent ofsales are in emerging markets - offers a strong platform forproducts from CareFusion, which currently relies on the domesticmarket for 75 percent of its revenue.

Becton said the transaction is expected to providedouble-digit earnings growth, on an adjusted basis, in the firstfull year, and will be accretive to net earnings in fiscal year2018.

The deal, subject to regulatory and CareFusion shareholderapprovals and customary closing conditions, is expected to closein the first half of next year.

At closing, the companies said Becton Dickinson shareholderswill own around 92 percent of the combined company andCareFusion shareholders will own around 8 percent.

Healthcare companies have been merging at a record pace,with year-to-date activity topping $346 billion, compared to$212 billion in the year-ago period, Thomson Reuters data showed as of September.

Recent large deals have included AbbVie Inc's planned $54 billion acquisition of Shire Plc andMedtronic Inc's planned acquisition of Covidien Plc for $43 billion. AstraZeneca Plc, meanwhile,fended off a $118 billion takeover attempt by Pfizer Inc. (Reporting By Deena Beasley; Editing by Chizu Nomiyama)

More News
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.